|
|
Vaccine Detail
|
QS-21-Derived Saponin–Poliovirus T-Helper Epitope–(Tn)MUC1 (Glyco)peptide Tricomponent Vaccine |
| Vaccine Information |
- Vaccine Name: QS-21-Derived Saponin–Poliovirus T-Helper Epitope–(Tn)MUC1 (Glyco)peptide Tricomponent Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Conjugate vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Antigen: MUC1 (Pifferi et al., 2023)
- Immunization Route: subcutaneous injection
- Description: A fully synthetic, tricomponent anticancer vaccine consisting of a QS-21-derived minimal saponin adjuvant covalently linked to a poliovirus-derived helper T-cell epitope (PV103-115, KLFAVWKITYKDT) and tumor-associated (Tn)MUC1 (glyco)peptide antigens. The vaccine exists in two variants: compound 6 (QA(PV)–MUC1) containing MUC1 peptide and compound 7 (QA(PV)–TnMUC1) containing TnMUC1 glycopeptide with Tn carbohydrate (GalNAc-α-O-Thr) on the SAPDTRPAP epitope. The three components are covalently conjugated via chemoselective ligation, creating a self-adjuvanting vaccine that spontaneously self-assembles into stable particulate aggregates in aqueous solution. Vaccination of C57BL/6 mice via subcutaneous injection (2-3 bi-weekly doses) with tricomponent vaccines induced significant anti-(Tn)MUC1 IgG antibodies (predominantly IgG1 and IgG2b subtypes) that recognized native TA-MUC1 on MCF7 cancer cells. Di-component constructs lacking the PV helper epitope or non-conjugated admixtures failed to elicit comparable responses, demonstrating that covalent linkage of all three components is required for immunogenicity. NMR studies revealed that tricomponent vaccines form stable, dilution-resistant nanostructures with surface-exposed (Tn)MUC1 antigens, while di-component constructs showed partial aggregate disruption upon dilution, correlating with reduced immunogenicity (Pifferi et al., 2023).
|
| Host Response |
|
|
| References |
Pifferi et al., 2023: Pifferi C, Aguinagalde L, Ruiz-de-Angulo A, Sacristán N, Baschirotto PT, Poveda A, Jiménez-Barbero J, Anguita J, Fernández-Tejada A. Development of synthetic, self-adjuvanting, and self-assembling anticancer vaccines based on a minimal saponin adjuvant and the tumor-associated MUC1 antigen. Chemical science. 2023; 14(13); 3501-3513. [PubMed: 37006677].
|
|
